Uses
Side effects
Interactions
Precautions
How Vyvanse (Lisdexamfetamine) works
VYVANSE is a central nervous system (CNS) stimulant indicated for the treatment of (1):
- Attention Deficit Hyperactivity Disorder (ADHD)
- Moderate to Severe Binge Eating Disorder (BED)
- Limitation of Use: VYVANSE is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established.
What are the side effects of Vyvanse (Lisdexamfetamine)?
Most common adverse reactions (incidence >5% and at a rate at least twice placebo) in children, adolescents, and/or adults with ADHD were:
- anorexia
- anxiety
- decreased appetite
- decreased weight
- diarrhea
- dizziness
- dry mouth
- irritability
- insomnia
- nausea
- upper abdominal pain
- vomiting
- Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine.
- Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Adjust VYVANSE dosage accordingly
- Serious Cardiovascular Reactions: Sudden death in children and adolescents with serious heart problems, as well as sudden death, stroke, and myocardial infarction in adults reported. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, or coronary artery disease
- Blood Pressure and Heart Rate Increases: Monitor blood pressure and pulse. Consider benefits and risks before use in patients for whom blood pressure increases may be problematic
- Psychiatric Adverse Reactions: May cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychosis. Evaluate for bipolar disorder prior to stimulant use
- Suppression of Growth: Monitor height and weight in pediatric patients during treatment
- Peripheral Vasculopathy, including Raynaud’s phenomenon: Stimulants are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Careful observation for digital changes is necessary during treatment with stimulants
